Approval date: 3 Oct. 2019
Brand name: Hemady
Innovator: Dexcel
Indication: in combination with other anti-myeloma products for the treatment of adults with multiple myeloma
Excipients: corn starch, lactose monohydrate, magnesium stearate, povidone, and sodium starch glycolate
Advantage of Hemady:
Previously approved Dexamethasone tablets are available in 0.5mg, 0.75mg, 1mg, 1.5mg, 2mg, 4mg and 6mg variants. During treatment of Multiple Myeloma with Lenalidomide, Pomalidomide and Thalidomide, oral Dexamethasone is administered in an amount of either 20mg/day or 40mg/day. Hence, multiple units of Dexamethasone tablets are administered to achieve the dose requirement of 20 mg/day or 40 mg/day.
Dexcel’s Hemady is the first oral dexamethasone tablet which comes with 20 mg variant. Accordingly, it will reduce the pill burden for the multiple myeloma patients who are taking oral Dexamethasone in combination with other anti-myeloma products.
Source: Prescribing Information
If you need information on patents/patent applications covering Dexcel’s Hemady, then write us at pharmacaption@gmail.com
No comments:
Post a Comment